Sera Prognostics Inc (SERA) Q3 2024 Earnings Call Transcript Summary
Sera Prognostics Inc (SERA) Q3 2024 Earnings Call Transcript Summary
Net loss for Q3 2024 increased to $7.9 million from $7.2 million in Q3 2023.The following is a summary of the Sera Prognostics Inc (SERA) Q3 2024 Earnings Call Transcript:
以下是Sera Prognostics Inc（SERA）2024年第三季度业绩会议记录摘要：
Financial Performance:
财务表现:
Net revenue for Q3 2024 was $29,000, a decrease from $42,000 in the same period a year ago.
Total operating expenses for Q3 2024 were $8.9 million, up 8% from $8.2 million in Q3 2023.
Net loss for Q3 2024 increased to $7.9 million from $7.2 million in Q3 2023.
2024年第三季度净营业收入为29,000美元，较一年前的42,000美元下降。
2024年第三季度总营业费用为890万美元，比2023年第三季度的820万美元增长了8%。
2024年第三季度净亏损从2013年第三季度的720万美元上升至790万美元。
Business Progress:
业务进展：
Focused on publication of clinical trial results and expanding test adoption and payer coverage.
Launched educational campaigns with significant engagement and initiated direct-to-consumer sales through new online platforms.
Continued growth in visibility and adoption through media campaigns and social media presence.
专注于发布临床试验结果并扩大测试采用率和支付者覆盖范围。
通过新的在线平台启动了具有重大参与度的教育宣传活动，并推出了直接面向消费者销售。
通过媒体宣传和在社交媒体上的存在，能够进一步提升知名度和用户采用率。
Opportunities:
机会：
Addressing increased rates of preterm births in the U.S., a significant health care challenge, via educational and awareness campaigns.
Expanding direct-to-consumer access to PreTRM tests, enhancing potential for revenue growth.
通过教育和意识活动来应对美国早产率上升，这是一个重要的医疗保健挑战。
扩大直接面向消费者推广PreTRm检测，提升营业收入增长潜力。
Risks:
风险：
Slow scaling of AI services may delay expected revenue growth from these innovations.
人工智能服务的缓慢扩展可能会延迟这些创新预期营业收入增长。
Tips: This article is generated by AI. The accuracy of the content can not be fully guaranteed. For more comprehensive details, please refer to the IR website. The article is only for investors' reference without any guidance or recommendation suggestions.
提示：本文由人工智能生成。内容准确性无法完全保证。如需更全面详情，请参阅IR网站。本文仅供投资者参考，不具有任何指导或推荐建议。
